A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

With studies showing potential for SGLT2 inhibitors in heart failure ... Others were concerned that there was uncertainty about the mechanism. Cost was also a concern raised by cautious ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug Administration (FDA) to treat type 2 diabetes can also reduce heart attacks and ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular ...

Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...

If you continue to have this issue please contact [email protected]. Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also ...

Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...